Department of Orthopedic Center, Sunshine Union Hospital, Weifang, 261000, Shandong, PR China.
Department of Orthopedic Center, Sunshine Union Hospital, Weifang, 261000, Shandong, PR China.
Toxicon. 2023 Jul;230:107174. doi: 10.1016/j.toxicon.2023.107174. Epub 2023 May 24.
Steroid-induced avascular necrosis of femoral head (SANFH) is one of the most common complications caused by long-term or excessive clinical use of glucocorticoids. This study aimed to investigate the effects of dried root of Rehmannia glutinosa extracts (DRGE) in SANFH. First, SANFH rat model was established by dexamethasone (Dex). Tissue change and proportion of empty lacunae were detected by hematoxylin and eosin staining. Protein levels were detected by western bloting analysis. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed to assess apoptosis of femoral head tissue. Cell viability and apoptosis of MC3T3-E1 cells were assessed by Cell Counting Kit-8 assay and flow cytometry. ALP activity and cell mineralization were detected by ALP staining assay and Alizarin red staining. The findings showed that DRGE improved tissue damage, inhibited apoptosis, and promoted osteogenesis in SANFH rats. In vitro, DRGE increased cell viability, inhibited cell apoptosis, promoted osteoblast differentiation, reduced the levels of p-GSK-3β/GSK-3β, but increased the levels of β-catenin in cells treated with Dex. Furthermore, DKK-1, an inhibitor of the wingless-type (Wnt)/β-catenin signaling pathway, reversed the effect of DRGE on cell apoptosis and ALP activity in cells treated with Dex. In conclusion, DRGE prevents SANFH by activating the Wnt/β-catenin signaling pathway, indicating that DRGE may be a hopeful choice drug to prevent and treat patients with SANFH.
丹红注射液联合甲钴胺治疗糖尿病周围神经病变的临床研究
目的 观察丹红注射液联合甲钴胺治疗糖尿病周围神经病变(DPN)的临床疗效。
方法 将 96 例 DPN 患者随机分为观察组和对照组各 48 例。对照组给予甲钴胺治疗,观察组在对照组治疗基础上加用丹红注射液治疗。2 组均治疗 2 周。观察 2 组临床疗效,治疗前后检测 2 组正中神经、腓总神经的运动神经传导速度(MCV)和感觉神经传导速度(SCV),并比较 2 组治疗前后多伦多临床评分系统(TCSS)评分。
结果 观察组总有效率为 93.75%,对照组为 79.17%,观察组疗效优于对照组(P<0.05)。治疗后 2 组正中神经、腓总神经的 MCV 和 SCV 均较本组治疗前升高(P<0.05),且观察组上述指标的改善均优于对照组(P<0.05)。治疗后 2 组 TCSS 评分均较本组治疗前降低(P<0.05),且观察组 TCSS 评分低于对照组(P<0.05)。
结论 丹红注射液联合甲钴胺治疗 DPN 可提高临床疗效,改善神经传导速度,降低 TCSS 评分。